Literature DB >> 31150704

Distinguishing Stevens-Johnson syndrome/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation-A retrospective chart review.

Allison Weinkle1, Cory Pettit2, Aditi Jani3, Jesse Keller4, Yuanyuan Lu5, Stephen Malachowski1, John C Trinidad2, Benjamin H Kaffenberger2, Elizabeth N Ergen3, Lauren C Hughey3, David Smith6, Lucia Seminario-Vidal7.   

Abstract

BACKGROUND: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening conditions that may present with similar findings to other severe dermatologic diseases.
OBJECTIVE: The primary objective of this exploratory study was to explore factors associated with SJS/TEN and develop a model that provides the predicted probability of SJS/TEN for patients for whom the diagnosis of SJS/TEN is considered.
METHODS: Retrospective review of consultations for patients with suspected SJS, TEN, or overlap at 4 academic dermatology consultation services.
RESULTS: Overall, 208 patients were included; 59 (28.4%) had a final diagnosis of SJS/TEN, and 149 (71.6%) were given a different diagnosis. The most common mimickers were drug hypersensitivity syndrome (n = 21, 10.1%), morbilliform drug eruption (n = 18, 8.7%), erythema multiforme (n = 15, 7.2%), and acute generalized exanthematous pustulosis (n = 13, 6.2%). Nikolsky sign, atypical targets, fever, and lymphopenia were included in a model for predicting the probability of SJS/TEN. LIMITATIONS: All cases were obtained from academic centers, which may limit the generalization of findings to community-based settings. This was an exploratory study with a small number of cases, and external validation of the model performance is needed.
CONCLUSION: Early dermatologic evaluation of patients with suspected SJS/TEN is key to separating patients with this condition from those who ultimately receive diagnoses of other serious skin diseases.
Copyright © 2019 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Stevens-Johnson syndrome; dermatology consultation; inpatient; severe cutaneous adverse reaction; toxic epidermal necrolysis

Mesh:

Year:  2019        PMID: 31150704     DOI: 10.1016/j.jaad.2019.05.061

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  7 in total

1.  Stevens-Johnson syndrome with a recall-like reaction within a donor graft site.

Authors:  Maleka Najmi; Leigha Sharp; Michelle Tarbox; Cloyce Stetson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-09-17

2.  Inpatient Dermatology Consultations in a General Surgery Ward in a Tertiary Hospital in China: A Retrospective Study of 251 Patients.

Authors:  Hanlin Zhang; Keyun Tang; Rouyu Fang; Hongzhong Jin; Qiuning Sun
Journal:  Dermatol Ther (Heidelb)       Date:  2021-04-22

3.  Patterns of Dermatological Diseases in Inpatient Consultations at King Abdulaziz Medical City, Jeddah, Saudi Arabia: An Underexploited Opportunity for Dermatology Clinical Training.

Authors:  Awadh Alamri; Mohammed Alshareef; Sarah B Aljoudi; Luai Assaedi; Sara Alkassimi; Abdulmohsin Algethami; Mazen S Dajam
Journal:  Cureus       Date:  2022-02-11

Review 4.  Inpatient Teledermatology: a Review.

Authors:  Joseph Mocharnuk; Trevor Lockard; Corey Georgesen; Joseph C English
Journal:  Curr Dermatol Rep       Date:  2022-04-02

5.  In Reply.

Authors:  Mario E Lacouture; Anisha B Patel; Jonathan E Rosenberg; Peter H O'Donnell
Journal:  Oncologist       Date:  2022-10-01       Impact factor: 5.837

6.  Acute generalized exanthematous pustulosis simulating toxic epidermal necrolysis: case presentation and literature review.

Authors:  Ana-Maria Copaescu; Danielle Bouffard; Marie-Soleil Masse
Journal:  Allergy Asthma Clin Immunol       Date:  2020-02-04       Impact factor: 3.406

7.  Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.

Authors:  Mario E Lacouture; Anisha B Patel; Jonathan E Rosenberg; Peter H O'Donnell
Journal:  Oncologist       Date:  2022-03-11       Impact factor: 5.837

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.